Anaphylaxis, asthma, severe hypersensitivity reactions.
Rheumatoid arthritis, juvenile chronic arthritis, polymyalgia rheumatica.
Systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease (other than systemic sclerosis), polyarteritis nodosa, sarcoidosis.
Pemphigus, bullous pemphigoid, pyoderma gangrenosum.
Minimal change nephrotic syndrome, acute interstitial nephritis.
Ulcerative colitis, Crohn’s disease.
Uveitis, optic neuritis.
Autoimmune haemolytic anaemia, idiopathic thrombocytopenic Purpura
Acute and lymphatic leukaemia, malignant lymphoma, multiple myeloma.
Immune suppression in transplantation.
- Rheumatoid arthritis: The maintenance dose is usually within the range 3 – 18 mg/day. The smallest effective dose should be used and increased if necessary.
- Bronchial asthma: In acute attack, high doses of 48 – 72 mg/ day may be needed depending on severity and gradually reduced once the attack has been controlled; in chronic asthma, doses should be titrated to the lowest dose that controls symptoms.
- Other conditions: The dose of deflazacort depends on clinical need titrated to the lowest effective dose for maintenance.
Children: There has been limited exposure of children to deflazacort. It is important that the lowest effective dosage is used.
- Juvenile chronic arthritis: The usual maintenance dose is between 0.25 – 1.0 mg/kg/day.
- Nephrotic syndrome: 1.5 mg/kg/day followed by down titration according to clinical need.
- Bronchial asthma: 0.25 – 1.0 mg/kg on alternate days.
Flazacort 6 is orally administered.